Glenmark Pharmaceuticals' (NSE:GLENMARK, BOM:532296) US-based arm Glenmark Pharmaceuticals Inc has launched its drug Clindamycin Phosphate Foam, 1%, according to a Wednesday filing to the Indian stock exchanges.

Glenmark's Clindamycin Phosphate Foam, 1%, is bioequivalent and therapeutically equivalent to Mylan Pharmaceuticals' reference listed drug Evoclin Foam, 1%.

Clindamycin Phosphate Foam is a topical treatment for acne, according to the company website.

Shares of the company were down over 2% in recent trade.